Regeneron adds Decibel to gene therapy playlist, turning up volume on long-running hearing loss collaboration Nektar CEO slams Eli Lilly's 'egregious error,' laments lost time for rezpeg Terns, trailing rivals, hits in phase 2 NASH trial but fails to quash differentiation doubts Novartis' BTK inhibitor hits hives in phase 3, teeing up filings to counter Dupixent threat Takeda, Denali drop Alzheimer's asset after phase 1 peak reveals 'narrow therapeutic window' After a 'reset', Beam aims to dose first patient in sickle cell trial this year Cash-strapped Salarius lays off more than 50% of staff as clinical ambitions prove too costly Flagship's Alltrna collects $109M as it passes go to Stop Codon Disease Palisade’s stock collapses as sole asset flunks phase 2 GI trial in post-surgery patients RNA biotech ADARx hauls in $200M, almost doubling two previous raises combined Cash-strapped Kiora sharpens focus on rare retinal diseases, looks to partner off other assets New Epstein-Barr vaccine may thwart infection and later disease, too | 